116 related articles for article (PubMed ID: 38311281)
1. The novel selective TLR7 agonist GY101 suppresses colon cancer growth by stimulating immune cells.
Ren SM; Chang JB; Liu RQ; Jin GY
Eur J Pharmacol; 2024 Mar; 967():176383. PubMed ID: 38311281
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
Wang D; Precopio M; Lan T; Yu D; Tang JX; Kandimalla ER; Agrawal S
Mol Cancer Ther; 2010 Jun; 9(6):1788-97. PubMed ID: 20515950
[TBL] [Abstract][Full Text] [Related]
4. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S
Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281
[TBL] [Abstract][Full Text] [Related]
5. A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma.
Lin G; Wang X; Yi W; Zhang C; Xu G; Zhu X; Cai Z; Liu Y; Diao Y; Lin MC; Jin G
J Transl Med; 2015 May; 13():166. PubMed ID: 25990580
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
7. Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity.
Huang CH; Mendez N; Echeagaray OH; Weeks J; Wang J; Vallez CN; Gude N; Trogler WC; Carson DA; Hayashi T; Kummel AC
ACS Appl Mater Interfaces; 2019 Jul; 11(30):26637-26647. PubMed ID: 31276378
[TBL] [Abstract][Full Text] [Related]
8. Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines.
Klauber TCB; Laursen JM; Zucker D; Brix S; Jensen SS; Andresen TL
Acta Biomater; 2017 Apr; 53():367-377. PubMed ID: 28153581
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 7 and 9 defects in common variable immunodeficiency.
Yu JE; Knight AK; Radigan L; Marron TU; Zhang L; Sanchez-Ramón S; Cunningham-Rundles C
J Allergy Clin Immunol; 2009 Aug; 124(2):349-56, 356.e1-3. PubMed ID: 19592080
[TBL] [Abstract][Full Text] [Related]
10. DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects.
Ota Y; Nagai Y; Hirose Y; Hori S; Koga-Yamakawa E; Eguchi K; Sumida K; Murata M; Umehara H; Yamamoto S
Front Immunol; 2023; 14():1055671. PubMed ID: 36793737
[TBL] [Abstract][Full Text] [Related]
11. B cell autophagy mediates TLR7-dependent autoimmunity and inflammation.
Weindel CG; Richey LJ; Bolland S; Mehta AJ; Kearney JF; Huber BT
Autophagy; 2015; 11(7):1010-24. PubMed ID: 26120731
[TBL] [Abstract][Full Text] [Related]
12. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
13. TLR7 Agonist Suppresses Group 2 Innate Lymphoid Cell-mediated Inflammation via IL-27-Producing Interstitial Macrophages.
Okuzumi S; Miyata J; Kabata H; Mochimaru T; Kagawa S; Masaki K; Irie M; Morita H; Fukunaga K
Am J Respir Cell Mol Biol; 2021 Sep; 65(3):309-318. PubMed ID: 34003734
[TBL] [Abstract][Full Text] [Related]
14. Nanoengineered Macrophages Armed with TLR7/8 Agonist Enhance Remodeling of Immunosuppressive Tumor Microenvironment.
Yoo YJ; Eun R; Park HM; Kim S; Park SH; Heo J; Lim YT
Small; 2024 Mar; 20(13):e2307694. PubMed ID: 37967333
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
[TBL] [Abstract][Full Text] [Related]
16. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.
Anguille S; Smits EL; Cools N; Goossens H; Berneman ZN; Van Tendeloo VF
J Transl Med; 2009 Dec; 7():109. PubMed ID: 20021667
[TBL] [Abstract][Full Text] [Related]
17. Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma.
Ou J; Zheng L; Chen Y; Fu Q; Tan L; Liang E; Huang L; Pan Y; Ke J; Chen Z; Cheng K
J Med Chem; 2024 Mar; 67(5):3321-3338. PubMed ID: 38363069
[TBL] [Abstract][Full Text] [Related]
18. The TLR7 agonist Imiquimod promote the immunogenicity of mesenchymal stem cells.
Zhang L; Liu D; Pu D; Wang Y; Li L; He Y; Li Y; Li L; Li W
Biol Res; 2015 Jan; 48(1):6. PubMed ID: 25654296
[TBL] [Abstract][Full Text] [Related]
19. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29.
Sirén J; Pirhonen J; Julkunen I; Matikainen S
J Immunol; 2005 Feb; 174(4):1932-7. PubMed ID: 15699120
[TBL] [Abstract][Full Text] [Related]
20. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rα) signaling.
Ferrante CJ; Pinhal-Enfield G; Elson G; Cronstein BN; Hasko G; Outram S; Leibovich SJ
Inflammation; 2013 Aug; 36(4):921-31. PubMed ID: 23504259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
